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Abstract 
 
Hypothesis: 
Rhodiola crenulata extract is derived from Tibetan plant’s roots and has been shown to 
have anti-cancer properties. Previously, we have shown that Rhodiola extract has toxic 
effects on B16 F10 mouse melanoma cells in vitro. The purpose of this project was to 
determine if a daily topical application of Rhodiola extract on melanoma tumors in mice 
leads to a reduction in tumor size and improved survival.      
 
Methods: 
1x106 B16F10 melanoma cells were subcutaneously injected above the scapular fat pad 
in C57/BL6 mice. Rhodiola extract was dissolved in a 10% DMSO Eucerine based 
cream. Twenty-four hours following tumor implantation, daily topical Rhodiola treatment 
began. Tumor volume measurements began on the fifth day of therapy and were 
measured daily thereafter.  
 
Results:  
Tumors treated with the topical Rhodiola cream tended to grow more radially, rather than 
vertically when compared to vehicle control.  Mice treated with the vehicle control 
reached a tumor volume of 500mm3 in 10 days, whereas mice treated with the 5% and 
10% Rhodiola reached a tumor volume of 500mm3 in 11 and 15 days respectively. All 
mice treated with vehicle control met requirements for euthanasia by day 14. In contrast, 
mice treated with the 5% Rhodiola met requirements for euthanasia by day 15 except for 
one mouse who exhibited tumor regression and survived for over 30 days. All mice 
treated with the 10% Rhodiola cream met requirements for euthanasia by day 20. 
 
Conclusion:    
Although analysis from our experiment is still in progress, we have observed a gross 
difference in tumors of mice treated with topical application of Rhodiola cream in 
comparison with mice treated with a topical application of a vehicle control cream. Future 
work will focus on histological evaluation of harvested tumors to determine microscopic 
differences in tumor characteristics. 
 
 
 
 
 
 
 
 
